: Delivered a 516% return as it dominated its niche in the metabolic disease market.
: Soared over 440% after announcing a gene therapy partnership with Pfizer . pharma stocks to buy 2017
: Led the industry in R&D spending, focused heavily on its blockbuster immunotherapy Keytruda . : Delivered a 516% return as it dominated